Last reviewed · How we verify
CyclASol®
At a glance
| Generic name | CyclASol® |
|---|---|
| Sponsor | Novaliq GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004 (PHASE3)
- ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (PHASE3)
- CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (PHASE2, PHASE3)
- CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED) (PHASE2)
- CyclASol® Phase 1 Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CyclASol® CI brief — competitive landscape report
- CyclASol® updates RSS · CI watch RSS
- Novaliq GmbH portfolio CI